Core Framework & Diagram Psoriasis
7 月 28, 20261 Min Read Inflammatory Bowel Disease
7 月 28, 2026The words 'skin disease' caused psoriasis to be underestimated for decades
——Psoriasis is the most visible systemic autoimmune war — playing out on your skin.
I. Why does psoriasis appear on the skin?
Why does psoriasis inflammation concentrate in the skin when it's a systemic autoimmune disease? This isn't coincidental. Skin is one of the body's largest immune organs, with large numbers of dendritic cells, T cells, and keratinocytes stationed there. Skin frequently experiences various physical and biological stimuli (friction, infection, UV), so it has highly active local immune surveillance.
Psoriasis outbreaks often begin with local skin stimulation — this is called the 'Koebner phenomenon': in psoriasis patients, sites on the skin that experience trauma, friction, or infection develop new psoriasis lesions. This shows skin's local immune response is the triggering point of the psoriasis inflammation cycle. Genetic susceptibility (especially HLA-C*06:02 genotype) determines whether skin immune cells, when they receive these stimuli, 'go off-course' onto the IL-23/Th17/IL-17A inflammatory track.
2. Systemic risks of psoriasis: skin is just the tip of the iceberg
What psoriasis patients face isn't only skin difficulties. Systemic chronic inflammation is psoriasis's most important 'hidden cost.' Persistently elevated inflammatory factors — TNF-α, IL-6, IL-17A — are simultaneously operating outside the skin.
Cardiovascular risk: moderate-to-severe psoriasis patients' myocardial infarction risk is approximately one and a half times that of the general population, with faster atherosclerosis progression — this risk exists independently of traditional cardiovascular risk factors. A large-scale 2006 JAMA study first established this association, changing the perception of psoriasis as purely a 'skin disease.' Metabolic syndrome (obesity, diabetes, hypertension, hyperlipidemia) occurs significantly more frequently in psoriasis patients than the general population.
Psoriatic arthritis (PsA) affects approximately thirty percent of psoriasis patients, can cause joint erosion and functional damage, and has pathological features different from rheumatoid arthritis requiring specialty management.
Understanding these systemic risks isn't to make patients more anxious, but to make psoriasis management more comprehensive — not only assessing how much skin lesions have cleared, but simultaneously assessing and managing cardiovascular risk, metabolic status, and signs of joint involvement.
3. Psoriasis's psychological impact: another underestimated battlefield
Psoriasis's impact on mental health is one of the most severe among similar skin diseases. Approximately thirty percent of psoriasis patients have clinically significant depression; anxiety rates are also significantly higher than the general population. This isn't only psychological pressure from appearance being affected — chronic inflammation itself (IL-6, TNF-α cytokines) has direct neurotoxic and neuroinflammatory effects on the brain, one of the important biological mechanisms of psoriasis-related depression.
Social avoidance is a very real predicament for psoriasis patients — avoiding swimming, exercise, intimate relationships, even social situations in work environments, all can be affected by the visibility of lesions. Research shows psoriasis's damage to quality of life, in some patients, is comparable to cancer, heart disease, and diabetes — this comparison isn't to emphasize pessimism, but to say: in psoriasis management, mental health is equally important to skin symptoms.
4. Treatment advances: from coal tar to precision targeting
Psoriasis treatment has evolved through several generations over the past hundred years. From the earliest coal tar (non-specific anti-inflammatory effects, effective for mild psoriasis but unpleasant odor) through topical corticosteroids (short-term effective, long-term skin atrophy risks), phototherapy (UVB and PUVA, using UV's immune suppressive effects), to systemic drugs (methotrexate, cyclosporine — effective but side effects limit long-term use), each generation improved but none precisely targeted the disease mechanism.
Biologic introduction was a paradigm shift. First-generation biologics targeted TNF-α (etanercept, infliximab, adalimumab), achieving fifty to seventy percent skin clearance in moderate-to-severe psoriasis. Then IL-12/23-targeting biologics (ustekinumab) and direct IL-17A-targeting biologics (secukinumab, ixekizumab) pushed complete or near-complete skin clearance rates (PASI 90/100) to seventy to ninety percent. The newest IL-23 p19 antagonists (risankizumab, guselkumab) are more selective with fewer side effects and require only two to four injections per year.
5. Lifestyle and psoriasis: the parts you can control
Weight reduction has significant effects on moderate-to-severe psoriasis. Multiple studies show obesity (especially visceral fat) is an independent predictor of psoriasis severity, while weight loss (even just five to ten percent) can reduce lesion severity and improve biologic treatment efficacy. Fat tissue secretes pro-inflammatory factors (TNF-α, IL-6, leptin) that directly feed the skin's inflammation cycle.
Quitting smoking has comprehensive effects: lowering disease risk, reducing disease severity, and improving treatment response. Stress management has direct outbreak control significance for psoriasis — mindfulness practice and cognitive behavioral therapy have shown improvements in psoriasis lesion severity in clinical research.
Frequently Asked Questions